Binding of monofluorophosphate to α2-macroglobulin and C3

Rigalli, Alfredo; Esteban, Luis; Pera, Laura; Rc, Puche

doi:10.1007/s002239900190

Cited by 8 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected, treatment with NaF increases the fasting levels of total and diffusible F for patients treated with sodium monofluorophosphate. On the other hand, the raised serum F levels are due to the increased proteinbound fraction, as reported elsewhere (7)(8)(9).…”

Section: Fasting Serum F Of Controls and Of Patients Chronically Treasupporting

confidence: 75%

Measurement of total and diffusible serum fluoride

Rigalli¹,

Alloatti²,

Puche³

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

This article describes a technique for the measurement of total and diffusible F content of serum, at clinical significant concentrations of F (1-10 microM). The proposed procedure avoids the interference of unknown serum components with the ion-specific electrode. Sample F is concentrated fivefold through distillation of hydrofluoric acid (Taves' method). Ionic fluoride is presented to the electrode in a simple solution at concentrations within the linear response of the electrode. Average recoveries of F from serum or its ultrafiltrate were 96+/-7% (21%) and 97+/-12% (53%) (mean+/-SEM [CV]), respectively. With four replicates of each sample, the technique produce within-run standard deviations of 0.6 microM and 2.2 microM at 1 and 10 microM F, respectively. Total precision assessment gave standard deviations of 0.6 microM and 2.6 microM at 1 and 10 microM F, respectively. The fasting serum F levels of normal climacteric women, 45 to 65 years, showed an asymmetric distribution. The data obtained started at the detection limit of the technique (0.1 mM). The 75 percentile was 1.85 microM for total and 0.5 microM for diffusible F. In patients (n = 25) treated with NaF (30 mg F/day) the fasting levels of total serum F (4.5 +/-1.7 microM) did not differ from those of diffusible F (4.2+/-1.5 microM). In patients (n = 50) treated with sodium monofluorophosphate (15 mg F/day) the fasting levels of total and diffusible serum F were 6.5+/-1.7 microM and 0.5+/-0.03 microM, respectively. In conclusion, this paper establishes the presence of two fractions of serum fluorine: diffusible and nondiffusible (or protein bound) and describes a technique for their clinical estimation. In untreated subjects and in patients receiving NaF, the former fraction contains ionic fluoride. In patients treated with MFP, diffusible serum fluorine is composed by ionic fluoride and low molecular weight, peptide-bound, acid-labile fluorine.

show abstract

Section: Fasting Serum F Of Controls and Of Patients Chronically Treasupporting

confidence: 75%

Measurement of total and diffusible serum fluoride

Rigalli¹,

Alloatti²,

Puche³

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

show abstract

“…On the other hand, the raised serum F levels are due to the increased proteinbound fraction, as reported elsewhere (7)(8)(9).…”

Section: Fasting Serum F Of Controls and Of Patients Chronically Treasupporting

confidence: 75%

“…The latter feature is often regarded as a negative one; but this way, a large number of samples can be handled simultaneously. The proposed technique has been used extensively in experimental and clinical work (7)(8)(9).…”

Section: F Species In Serummentioning

confidence: 99%

“…For untreated subjects, this fraction has not yet been characterized in terms of their chemical nature, sources, biological significance or fate. Work from this laboratory has shown that this fraction increases in rats and humans treated with MFP (7)(8)(9). The hypothesis has been advanced that the levels of nondiffusible F may be clinically important (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of total and diffusible serum fluoride

Rigalli¹,

Alloatti²,

Puche³

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

This article describes a technique for the measurement of total and diffusible F content of serum, at clinical significant concentrations of F (1–10 μM). The proposed procedure avoids the interference of unknown serum components with the ion‐specific electrode. Sample F is concentrated fivefold through distillation of hydrofluoric acid (Taves' method). Ionic fluoride is presented to the electrode in a simple solution at concentrations within the linear response of the electrode. Average recoveries of F from serum or its ultrafiltrate were 96 ± 7% (21%) and 97 ± 12% (53%) (mean ± SEM [CV]), respectively. With four replicates of each sample, the technique produce within‐run standard deviations of 0.6 μM and 2.2 μM at 1 and 10 μM F, respectively. Total precision assessment gave standard deviations of 0.6 μM and 2.6 μM at 1 and 10 μM F, respectively. The fasting serum F levels of normal climacteric women, 45 to 65 years, showed an asymmetric distribution. The data obtained started at the detection limit of the technique (0.1 mM). The 75 percentile was 1.85 μM for total and 0.5 μM for diffusible F. In patients (n = 25) treated with NaF (30 mg F/day) the fasting levels of total serum F (4.5 ± 1.7 μM) did not differ from those of diffusible F (4.2 ± 1.5 μM). In patients (n = 50) treated with sodium monofluorophosphate (15 mg F/day) the fasting levels of total and diffusible serum F were 6.5 ± 1.7 μM and 0.5 ± 0.03 μM, respectively.In conclusion, this paper establishes the presence of two fractions of serum fluorine: diffusible and nondiffusible (or protein bound) and describes a technique for their clinical estimation. In untreated subjects and in patients receiving NaF, the former fraction contains ionic fluoride. In patients treated with MFP, diffusible serum fluorine is composed by ionic fluoride and low molecular weight, peptide‐bound, acid‐labile fluorine. J. Clin. Lab. Anal. 13:151–157, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

“…Sodium monofl uorophosphate (MFP) is a drug used for the treatment of osteoporosis [ 8 ] that binds to plasma AM [ 9 ] . It has been demonstrated that the administration of MFP for 30 days increases plasma levels of AM in rats [ 10 , 11 ] and modifi es the course of pancreatitis [ 11 ] .…”

Section: Eff Ect Of the Treatment With Alpha-macroglobulin On The Devmentioning

confidence: 99%

Effect of the Treatment with Alpha-Macroglobulin on the Development of Experimental Pancreatitis

2013

Self Cite

View full text Add to dashboard Cite

pancreatitis without treatment, Enriched plasma: pancreatitis+-alpha-macroglobulin-enriched plasma, Normal plasma: pancreatitis+plasma with normal levels of alpha-macroglobulin, Saline Solution: pancreatitis+saline solution, Purified alpha-macroglobulin: pancreatitis+purified alpha-macroglobulin. After 14 days pancreatic damage was assessed using a score that measures: edema, fibrin, neutrophils, mononuclear leukocytes, necrosis, vascular congestion, thrombosis, hemorrhage and fibrosis. Pancreatic damage decreased and the percentage of animals with pancreatitis was lower in enriched-plasma and purified alpha-macroglobulin groups. We conclude that the intravenous administration of alpha-macroglobulins causes a reduction in the histological damage produced by pancreatitis.

show abstract

Binding of monofluorophosphate to α2-macroglobulin and C3

Cited by 8 publications

References 6 publications

Measurement of total and diffusible serum fluoride

Measurement of total and diffusible serum fluoride

Measurement of total and diffusible serum fluoride

Effect of the Treatment with Alpha-Macroglobulin on the Development of Experimental Pancreatitis

Contact Info

Product

Resources

About